New drug combo tested in patients with advanced cancers
NCT ID NCT04196530
Summary
This early-stage study tested the safety of an experimental drug called BDB001, given alone and combined with an existing immunotherapy (atezolizumab). It involved 40 adults with advanced solid tumors that had stopped responding to all standard treatments. The main goal was to find a safe dose and see how well patients tolerated the combination.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUMOR, SOLID are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Angeles Clinic
Los Angeles, California, 90025, United States
-
Florida Cancer Specialists
Sarasota, Florida, 34230, United States
-
NEXT Oncology
San Antonio, Texas, 78229, United States
-
South Texas Accelerated Research Therapeutics (START)
San Antonio, Texas, 78229, United States
-
Tennessee Oncology
Nashville, Tennessee, 37203, United States
Conditions
Explore the condition pages connected to this study.